1 March 2012 in Cell Metabolism
22 June 2016 in Biology of Reproduction
Recurrent pregnancy loss (RPL), which mostly is of unknown etiology ("unexplained RPL," uRPL), is defined as three or more consecutive spontaneous abortions. Some women with uRPL display a higher fraction and cytotoxicity of natural killer (NK) cells in the periphery and endometrium. Therefore, some uRPL cases have been explained by autoimmune abnormalities. The efficacy of intravenous immunoglobulin (IVIg) for uRPL has been confirmed in several clinical trials; however, its mechanism remains unknown, mainly because the abortion mechanism remains to be elucidated. In the present study, we analyzed the mechanisms of both abortion and IVIg action using an uRPL mouse model in which abortion was induced by lipopolysaccharide (LPS) injection. IVIg attenuated the abortion rate of uRPL model mice. And the suppressive effect of IVIg was maximized by high dose administration at early phase after LPS injection. Specifically, we discovered the presence of two distinct uterine NK (uNK) subsets: CD44bright and CD44mid. In uRPL model mice, we observed an increase in the number of CD44bright uNK cells, while the CD44mid uNK subset remained unchanged. Furthermore, when abortion was reduced by IVIg administration, the cell number of the CD44bright uNK subset did not increase, which might allow differentiating pathological from normal uNK cells based on CD44 expression. Based on these results, we propose not only an effective administration protocol of IVIg to the uRPL model mice, but also a novel mechanism of abortion related to the increase in the CD44bright subset and of IVIg, which suppresses the increase of the CD44bright subset.
1 January 2010 in Journal of Infection and Chemotherapy
1 May 2018 in Journal of Infection and Chemotherapy
Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infects healthy individuals, although the precise cause remains unclear. CA-MRSA produces Panton-Valentine leukocidin (PVL), which often causes severe invasive infection; however, antitoxin drugs against PVL are limited. Intravenous immunoglobulin (IVIg) possesses antitoxin activity, but unfortunately, the optimal dose is unknown. Here, we measured the PVL neutralizing antibody titer in the plasma of Japanese individuals and sera of American donors. Next, we compared the cytotoxic effects of PVL on neutrophils in phosphate buffered saline (PBS) or whole blood to determine the effect of the neutralizing antibody. Finally, we evaluated the effective concentration of IVIg required to neutralize PVL in PBS and whole blood. We observed that the titer of PVL neutralizing antibody in healthy individuals polarized as high and low/none group. Additionally, the PVL neutralizing antibody titer considerably affected the concentration at which IVIg elicited its effect. This suggests that PVL-producing CA-MRSA might be involved in determining the severity of infection in healthy individuals without neutralizing antibody against PVL. The neutralizing effect of IVIg was observed in both PBS and whole blood. However, the optimal concentration of IVIg required for neutralizing PVL varied between PBS and whole blood. In addition, since the PVL-neutralizing activity of IVIg also largely depends on blood composition, such as neutralizing antibody concentration, the optimal dosage of IVIg as an antitoxin drug should be decided in a timely manner after considering the patient's medical background.
1 January 1994 in Journal of Clinical Apheresis